Bicara Therapeutics BCAX Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's operating lease right-of-use assets in other assets?
- Bicara Therapeutics (BCAX) reported operating lease right-of-use assets in other assets of $1.43M in Q1 2026.
- How has Bicara Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
- Bicara Therapeutics's operating lease right-of-use assets in other assets increased by 158.7% year-over-year, from $552K to $1.43M.
- What is the long-term trend for Bicara Therapeutics's operating lease right-of-use assets in other assets?
- Over 2 years (2023 to 2025), Bicara Therapeutics's operating lease right-of-use assets in other assets has grown at a 66.6% compound annual growth rate (CAGR), from $613K to $1.7M.